Epigral Management

Management criteria checks 2/4

We currently do not have sufficient information about the CEO.

Key information

Kaushal Soparkar

Chief executive officer

₹43.9m

Total compensation

CEO salary percentage	9.2%
CEO tenure	8.5yrs
CEO ownership	0.5%
Management average tenure	no data
Board average tenure	8.5yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Kaushal Soparkar's remuneration changed compared to Epigral's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	₹3b
Jun 30 2024	n/a	n/a	₹3b
Mar 31 2024	₹44m	₹4m	₹2b
Dec 31 2023	n/a	n/a	₹2b
Sep 30 2023	n/a	n/a	₹2b
Jun 30 2023	n/a	n/a	₹3b
Mar 31 2023	₹62m	₹4m	₹4b
Dec 31 2022	n/a	n/a	₹4b
Sep 30 2022	n/a	n/a	₹4b
Jun 30 2022	n/a	n/a	₹3b
Mar 31 2022	₹32m	₹4m	₹3b
Mar 31 2021	₹30m	₹3m	₹1b
Mar 31 2020	₹28m	₹4m	₹1b
Mar 31 2019	₹64m	₹4m	₹2b
Mar 31 2018	₹9m	₹4m	₹2b

Compensation vs Market: Kaushal's total compensation ($USD519.99K) is above average for companies of similar size in the Indian market ($USD355.52K).

Compensation vs Earnings: Kaushal's compensation has been consistent with company performance over the past year.

CEO

Kaushal Soparkar (41 yo)

8.5yrs

Tenure

₹43,907,000

Compensation

Mr. Kaushal Ashisbhai Soparkar serves as Chief Executive Officer and until August 5, 2023 served as Managing Director and serves as Director of Epigral Limited (formerly known as Meghmani Finechem Limited)...

Board Members

Name	Position	Tenure	Compensation	Ownership
Maulik Patel	Chairman & MD	8.5yrs	₹43.91m	7.53% ₹ 6.3b
Kaushal Soparkar	CEO & Executive Director	8.5yrs	₹43.91m	0.51% ₹ 431.5m
Kanubhai Patel	Independent Non-Executive Director	3.5yrs	₹700.00k	no data
Karana Patel	Non-Executive Director	8.5yrs	₹25.32m	1.68% ₹ 1.4b
Sanjay Asher	Independent Non-Executive Director	3.5yrs	₹500.00k	no data
Ankit Patel	Non-Executive Director	8.5yrs	₹41.27m	5.41% ₹ 4.5b
Manubhai Patel	Independent Non-Executive Director	7.5yrs	₹875.00k	no data
Darshan Patel	Non-Executive Director	8.5yrs	₹17.35m	2.29% ₹ 1.9b
Nirali Parikh	Independent Non-Executive (Woman) Director	9.7yrs	₹725.00k	no data
Raju Swamy	Independent Non-Executive Director	3.5yrs	₹400.00k	0.010% ₹ 8.4m

8.5yrs

Average Tenure

43yo

Average Age

Experienced Board: 543332's board of directors are considered experienced (8.5 years average tenure).

Epigral Management

Management criteria checks 2/4

Key information

Recent management updates

Epigral Limited, Annual General Meeting, Jul 09, 2024

Insufficient new directors

Insider recently bought ₹4.8m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Insider recently bought ₹4.6m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Recent updates

Second quarter 2025 earnings released: EPS: ₹19.57 (vs ₹9.14 in 2Q 2024)

Epigral Limited to Report Q2, 2025 Results on Nov 09, 2024

Investor sentiment improves as stock rises 16%

New minor risk - Share price stability

First quarter 2025 earnings released: EPS: ₹20.67 (vs ₹7.58 in 1Q 2024)

Epigral Limited to Report Q1, 2025 Results on Jul 24, 2024

Epigral Limited Approves Final Dividend for the Financial Year 2024

Investor sentiment improves as stock rises 16%

Upcoming dividend of ₹5.00 per share

Full year 2024 earnings released: EPS: ₹47.14 (vs ₹85.03 in FY 2023)

Dividend of ₹5.00 announced

Epigral Limited, Annual General Meeting, Jul 09, 2024

Insufficient new directors

Full year 2024 earnings released: EPS: ₹47.13 (vs ₹85.03 in FY 2023)

Epigral Limited Recommends Final Dividend for the Financial Year Ended March 31, 2024

Epigral Limited to Report Q4, 2024 Results on Apr 22, 2024

Investor sentiment improves as stock rises 22%

Investor sentiment improves as stock rises 22%

Third quarter 2024 earnings released: EPS: ₹11.81 (vs ₹18.58 in 3Q 2023)

Now 23% overvalued after recent price rise

Epigral Limited to Report Q3, 2024 Results on Jan 24, 2024

New minor risk - Profit margin trend

Second quarter 2024 earnings released: EPS: ₹9.14 (vs ₹22.04 in 2Q 2023)

Epigral Limited to Report Q2, 2024 Results on Nov 06, 2023

First quarter 2024 earnings released: EPS: ₹7.58 (vs ₹25.94 in 1Q 2023)

Meghmani Finechem Limited to Report Q1, 2024 Results on Aug 05, 2023

Meghmani Finechem Limited Approves Final Equity Dividend for the Financial Year 2022-2023

Upcoming dividend of ₹2.50 per share at 0.5% yield

Insider recently bought ₹4.8m worth of stock

Meghmani Finechem Limited Proposes Final Dividend to the Shareholders for Financial Year 2022- 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Insider recently bought ₹4.6m worth of stock

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2023

Full year 2023 earnings released: EPS: ₹85.03 (vs ₹60.84 in FY 2022)

Investor sentiment improves as stock rises 18%

Chairman & MD recently bought ₹4.8m worth of stock

Chairman & MD recently bought ₹2.9m worth of stock

Insider recently bought ₹5.0m worth of stock

Third quarter 2023 earnings released: EPS: ₹18.68 (vs ₹23.85 in 3Q 2022)

Meghmani Finechem Limited Declares Maiden Interim Dividend for the Year Financial Year 2022-23, Payable on or After 08 February, 2023

Meghmani Finechem Limited to Report Q3, 2023 Results on Jan 19, 2023

Second quarter 2023 earnings released: EPS: ₹22.04 (vs ₹23.85 in 2Q 2022)

Investor sentiment deteriorated over the past week

First quarter 2023 earnings released: EPS: ₹25.94 (vs ₹7.89 in 1Q 2022)

Meghmani Finechem Limited to Report Q1, 2023 Results on Jul 21, 2022

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Meghmani Finechem Limited, Annual General Meeting, Jun 27, 2022

Investor sentiment improved over the past week

Full year 2022 earnings released: EPS: ₹60.84 (vs ₹24.27 in FY 2021)

Investor sentiment improved over the past week

Meghmani Finechem Limited to Report Fiscal Year 2022 Results on Apr 25, 2022

Investor sentiment improved over the past week

CEO, MD & Director recently bought ₹799k worth of stock

Insider recently bought ₹762k worth of stock

Investor sentiment improved over the past week

Insider recently bought ₹8.3m worth of stock

Investor sentiment improved over the past week

No independent directors

No independent directors

No independent directors

No independent directors

MD & Additional Director recently bought ₹5.0m worth of stock

No independent directors

CEO Compensation Analysis

CEO

Tenure

Compensation

Board Members